A prospective observational study on drug-drug interactions in chronic kidney disease patients

  • T. Rushinaidu Assistant professor in Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Vizianagaram
    randeep.clinosol@gmail.com
  • S. V. Sri Alekhya Student of Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Vizianagaram
  • Ch. Bhagya Sri Student of Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Vizianagaram
  • R.Harshavardhini Student of Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Vizianagaram
  • P. Rashmitha Student of Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Vizianagaram
  • G. Swetha Student of Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Vizianagaram

Abstract

Aim: To review Drug-Drug interactions among CKD patients.


Methodology: A concurrent conciliation study was performed on CKD patients with drug-drug interactions admitted in and around tertiary government and corporate hospitals, Visakhapatnam, Andhra Pradesh, India. Information regarding gender, and variety of drug interactions as mild, moderate, and major were recorded in the standard questionnaire.


Result: Overall 150 prescriptions were included after excluding missing data. The impact of concomitant disease in causing drug-drug interactions in 150 prescriptions them were Hypertension -35%,


Diabetes Mellitus-19%, Hyperlipidemia-8%, Asthma- 7%, Seizures- 6%, Thyroid -5%, Congestive Heart Failure- 1%. Total of 201 interactions were revealed of which 15 were major interactions, 139 were moderate interactions, 47 were minor interactions.


Conclusion: By assessing the above data it absolutely was concluded that the patient should possess sound knowledge of drug interactions before employing a selected drug or two or more drugs at the identical time so as to possess identical medication. 

Keywords: Chronic Kidney Disease, Drug-Drug interactions

Downloads

Download data is not yet available.

References

1. K.D., Essentials of Medical Pharmacology, 6th Edition, Jaypee Brothers, Medical Publishers (P) 111Ltd., Page- 889-896.
2. Tripathi Patidar Dindayal., Pharmacology-IV (Clinical and Drug Interactions), Shree Sai Prakashan, Meerut.
3. Scott R. Penzak, Pharm.D. Director, Clinical Pharmacokinetics Research Laboratory Clinical Centre Pharmacy Department National Institutes of Health December 9, 2010
4. Chris Raich, Pharm. D. candidate; Marie Abate, Pharm. D. Teri Dunsworth, Pharm. D., WVU School of Pharmacy ,Drug Information Center, West Virginia University extension service.
5. Chronic kidney disease – medical news today. About Chronic Kidney Disease. (n..). Retrieved from
https://www.kidney.org/atoz/content/about-chronic-kidney-disease
6. Bell JS, Blacker N, Leblanc VT, Alderman CP, Phillips A, Rowett D, et al. Prescribing for older people with chronic renal impairment. Aust Fam Physician2013;42:24
7. Corsonello A, Pedone C, Corica F, Mussi C, Carbonin P, Antonelli R, et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med2005;165:790-5.
8. Pharmaceutical Care Network Europe (PCNE) Foundation. The PCNE classification scheme for drug related problems V 6.2;2010 (Cited 2016 Oct 30). Available from:
http://www.pcne.org/upload/files/11_PCNE_classification_V62.pdf
9. Akici A, Oktay S. Rational pharmacotherapy and pharmacovigilance. Curr Drug Saf2007;2:65-9.
10. Meyboom RH, Lindquist M, Egberts AC. An ABC of drugrelated problems. Drug Saf2000;22:415-23
11. KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis2006;47:11145.
12. Kidney Disease Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney
IntSuppl2012;3:1-150. (Cited 2016 Oct 31). Available from:
http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD?KDI GO_2012_CKD_GL.pdf
13. Marquito AB, Fernandes NM, Colugnati FA, de Paula RB. Identifying potential drug interactions in chronic kidney disease patients. J BrasNefrol2014;36:26-34.
14. Rama M, Viswanathan G, Acharya LD, Attur RP, Reddy PN,Raghavan SV, et al. Assessment of drug-drug Iinteractions among renal failure patients of nephrology ward in a South Indian tertiary care hospital. Indian J Pharm Sci2012;74:63-8.
15. Bastos MG. Drug-drug interaction. J BrasNefrol2014;36:8.
16. RxList. Drug interactions checker (Cited 2016 Oct I30). Available from: http://www.rxlist.com/drug-interactionchecker.htm
17. UMHS Chronic Kidney Disease Guideline, March 2014. (Cited 2016 Oct 29). Available from: http://www.med.umich.edu/1info/FHP/practiceguides/kidney/CK .pdf
18. Ghanbari Y, Nagaraju K. Identifying drug-drug interaction among chronic kidney disease patients in tertiary care Ihospital. IntResJPharm2016;7:54-6.
19. Jones SA, Bhandari S. The prevalence of potentially inappropriate medication prescribing in elderly patients with chronic kidney disease. Postgrad Med J2013;89:247-50.
20. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care2008;35:329.
21. Al-Ramahi R, Raddad AR, Rashed AO, Bsharat A, AbuGhazaleh DA, Yasin E, et al. Evaluation of potential drug-drug interactions among Palestinian hemodialysis patients. BMC Nephro2016;17:96.

22. Merlo J, Liedholm H, Lindblad U, Björck-Linné A, Fält J, Lindberg G, et al. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. IBMJ I2001;323:427-8
23. Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lesserson DS, Hobbs FD. Global prevalence of chronic kidney disease: a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. [PMC free article] [PubMed] [Google Scholar]
24. Kadiri S, Arije A. Temporal variations and meteorological factors in hospital admissions of chronic renal failure in South West Nigeria. West Afr J Med. 1999;18(1):49–51. [PubMed] [Google IScholar]
25. Akinsola W, Odesanmi WO, Ogunniyi JO, Ladipo GO. Diseases causing chronic renal failure in Nigerians – a prospective study of 100 cases. Afr J Med Med Sci. 1989;18(2):131–137.
26. Ulasi II, joma CK, Onodugo OD, Arodiwe EB, febunandu NA, Okoye JU. Towards prevention of chronic kidney disease Iin Nigeria: a community-based study in Southeast Nigeria. Kidney Int Suppl. 2013;3(2):195–201. [Google Scholar)
27. Oluyombo R, Ayodele OE, Akinwusi PO, et al. A community study of the prevalence, risk factors and pattern of chronic kidney disease in Osun State, South West Nigeria. West Afr J Med. 2013;32(2):85–92. [PubMed] [Google Scholar]
28. Liu M, Li XC, Lu L, et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci. 2014;18(9):2918–2926. [PubMed] [Google Scholar]
29. Levin A, Hemmelgarn B, Culleton B, et al. Guidelines for the management of chronic kidney disease. CMAJ. 2008;179(11):1154–1162. [PMC free article][PubMed] [Google Scholar]
30. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–663. [PubMed] [Google Scholar]
Published
26/04/2022
Statistics
30 Views | 4 Downloads
Citatons
How to Cite
T, R., V. S. A. S, B. S. Ch, H. R, R. P, and S. G. “A Prospective Observational Study on Drug-Drug Interactions in Chronic Kidney Disease Patients ”. International Journal of Health Care and Biological Sciences, Vol. 3, no. 2, Apr. 2022, pp. 29-37, doi:10.46795/ijhcbs.v3i2.307.
Section
Research Articles